{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:28:36Z","timestamp":1789450116037,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"national government"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.vaccine.2012.12.031","type":"journal-article","created":{"date-parts":[[2012,12,27]],"date-time":"2012-12-27T16:45:35Z","timestamp":1356626735000},"page":"1065-1071","source":"Crossref","is-referenced-by-count":45,"title":["Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease"],"prefix":"10.1016","volume":"31","author":[{"given":"Patricia","family":"Kaaijk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ineke","family":"van Straaten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"van de Waterbeemd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmieke P.J.","family":"Boot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lonneke M.A.R.","family":"Levels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry H.","family":"van Dijken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germie P.J.M.","family":"van den Dobbelsteen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"November (8775)","key":"10.1016\/j.vaccine.2012.12.031_bib0005","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","article-title":"Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway","volume":"338","author":"Bjune","year":"1991","journal-title":"Lancet"},{"issue":"December (2)","key":"10.1016\/j.vaccine.2012.12.031_bib0010","first-page":"195","article-title":"Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba","volume":"14","author":"Sierra","year":"1991","journal-title":"NIPH Ann"},{"issue":"February (9)","key":"10.1016\/j.vaccine.2012.12.031_bib0015","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.vaccine.2005.09.043","article-title":"Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control","volume":"24","author":"Thornton","year":"2006","journal-title":"Vaccine"},{"issue":"June (Suppl. 2)","key":"10.1016\/j.vaccine.2012.12.031_bib0020","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2009.04.071","article-title":"Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis","volume":"27","author":"Holst","year":"2009","journal-title":"Vaccine"},{"issue":"June (9)","key":"10.1016\/j.vaccine.2012.12.031_bib0025","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0264-410X(94)00037-N","article-title":"Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease","volume":"13","author":"Boslego","year":"1995","journal-title":"Vaccine"},{"issue":"October (8827)","key":"10.1016\/j.vaccine.2012.12.031_bib0030","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0140-6736(92)93086-3","article-title":"Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil","volume":"340","author":"de Moraes","year":"1992","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2012.12.031_bib0035","first-page":"113","article-title":"Teasing apart structural determinants of \u2018toxicity\u2019 and \u2018adjuvanticity\u2019: implications for meningococcal vaccine development","volume":"10","author":"Steeghs","year":"2004","journal-title":"J Endotoxin Res"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2012.12.031_bib0040","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1128\/IAI.73.7.4070-4080.2005","article-title":"Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination","volume":"73","author":"Fisseha","year":"2005","journal-title":"Infect Immun"},{"issue":"July (2)","key":"10.1016\/j.vaccine.2012.12.031_bib0045","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1086\/589308","article-title":"Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin","volume":"198","author":"Koeberling","year":"2008","journal-title":"J Infect Dis"},{"issue":"July (10)","key":"10.1016\/j.vaccine.2012.12.031_bib0050","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/0264-410X(96)00020-5","article-title":"Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine","volume":"14","author":"Claassen","year":"1996","journal-title":"Vaccine"},{"issue":"July (30)","key":"10.1016\/j.vaccine.2012.12.031_bib0055","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1016\/j.vaccine.2010.04.082","article-title":"Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process","volume":"28","author":"van de Waterbeemd","year":"2010","journal-title":"Vaccine"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2012.12.031_bib0060","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1128\/IAI.69.10.5981-5990.2001","article-title":"Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity","volume":"69","author":"van der Ley","year":"2001","journal-title":"Infect Immun"},{"issue":"August (8)","key":"10.1016\/j.vaccine.2012.12.031_bib0065","doi-asserted-by":"crossref","first-page":"886","DOI":"10.4161\/hv.7.8.16086","article-title":"Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants","volume":"7","author":"van der Ley","year":"2011","journal-title":"Hum Vaccine"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2012.12.031_bib0070","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CVI.00403-08","article-title":"Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2","volume":"16","author":"Koeberling","year":"2009","journal-title":"Clin Vaccine Immunol"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2012.12.031_bib0075","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1128\/CVI.00342-09","article-title":"Evaluation of a whole-blood cytokine release assay for use in measuring endotoxin activity of group B Neisseria meningitidis vaccines made from lipid A acylation mutants","volume":"17","author":"Stoddard","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"December (12)","key":"10.1016\/j.vaccine.2012.12.031_bib0080","doi-asserted-by":"crossref","first-page":"5939","DOI":"10.1128\/IAI.00846-07","article-title":"Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B","volume":"75","author":"Fransen","year":"2007","journal-title":"Infect Immun"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2012.12.031_bib0085","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1128\/IAI.67.10.4988-4993.1999","article-title":"Immunogenicity of outer membrane proteins in a lipopolysaccharide-deficient mutant of Neisseria meningitidis: influence of adjuvants on the immune response","volume":"67","author":"Steeghs","year":"1999","journal-title":"Infect Immun"},{"issue":"March (13)","key":"10.1016\/j.vaccine.2012.12.031_bib0090","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1016\/j.vaccine.2006.09.025","article-title":"Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs","volume":"25","author":"van den Dobbelsteen","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.12.031_bib0095","series-title":"Program and abstracts of the 16th International Pathogenic Neisseria Conference","article-title":"Safety of a nonavalent meningococcal serogroup B vaccine in healthy adult volunteers in a randomised, controlled, single blind study","author":"Rots","year":"2008"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2012.12.031_bib0100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1574-6976.2006.00053.x","article-title":"Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines","volume":"31","author":"Trotter","year":"2007","journal-title":"FEMS Microbiol Rev"},{"issue":"March (4)","key":"10.1016\/j.vaccine.2012.12.031_bib0105","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0264-410X(95)98264-B","article-title":"Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine","volume":"13","author":"van der Ley","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.12.031_bib0110","doi-asserted-by":"crossref","unstructured":"Kaaijk P, van der Ark AAJ, van Amerongen G, van den Dobbelsteen GPJM. Nonclinical vaccine safety evaluation: advantages of continuous temperature monitoring using abdominally implanted data loggers. J Appl Toxicol; 2012 Mar 8, http:\/\/dx.doi.org\/10.1002\/jat.2720, in press.","DOI":"10.1002\/jat.2720"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2012.12.031_bib0115","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/ijc.2910410324","article-title":"Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes","volume":"41","author":"Ziegler-Heitbrock","year":"1988","journal-title":"Int J Cancer"},{"issue":"December (5)","key":"10.1016\/j.vaccine.2012.12.031_bib0120","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/bit.22016","article-title":"Modeling Neisseria meningitidis B metabolism at different specific growth rates","volume":"101","author":"Baart","year":"2008","journal-title":"Biotechnol Bioeng"},{"issue":"May (24)","key":"10.1016\/j.vaccine.2012.12.031_bib0125","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1016\/j.vaccine.2012.03.028","article-title":"Identification and optimization of critical process parameters for the production of NOMV vaccine against Neisseria meningitidis","volume":"30","author":"van de Waterbeemd","year":"2012","journal-title":"Vaccine"},{"issue":"July (1\u20132)","key":"10.1016\/j.vaccine.2012.12.031_bib0130","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0014-5793(00)01720-8","article-title":"Structure of the Bordetella pertussis 1414 endotoxin","volume":"477","author":"Caroff","year":"2000","journal-title":"FEBS Lett"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2012.12.031_bib0135","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1128\/IAI.71.11.6367-6371.2003","article-title":"Relative immunogenicity of PorA subtypes in a multivalent Neisseria meningitidis vaccine is not dependent on presentation form","volume":"71","author":"Luijkx","year":"2003","journal-title":"Infect Immun"},{"issue":"October (46)","key":"10.1016\/j.vaccine.2012.12.031_bib0140","doi-asserted-by":"crossref","first-page":"5883","DOI":"10.1016\/j.vaccine.2008.07.105","article-title":"Reactogenicity of infant whole cell pertussis combination vaccine compared with acellular pertussis vaccines with or without simultaneous pneumococcal vaccine in the Netherlands","volume":"26","author":"David","year":"2008","journal-title":"Vaccine"},{"issue":"March (1\u20132)","key":"10.1016\/j.vaccine.2012.12.031_bib0145","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jim.2005.01.010","article-title":"International validation of novel pyrogen tests based on human monocytoid cells","volume":"298","author":"Hoffmann","year":"2005","journal-title":"J Immunol Methods"},{"issue":"March (1\u20132)","key":"10.1016\/j.vaccine.2012.12.031_bib0150","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0022-1759(02)00519-7","article-title":"A rapid \u2018one-plate\u2019 in vitro test for pyrogens","volume":"274","author":"Poole","year":"2003","journal-title":"J Immunol Methods"},{"issue":"August (3)","key":"10.1016\/j.vaccine.2012.12.031_bib0155","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0022-1759(82)90004-7","article-title":"The detection of endotoxin by in vitro production of endogenous pyrogen: comparison with limulus amebocyte lysate gelation","volume":"52","author":"Duff","year":"1982","journal-title":"J Immunol Methods"},{"issue":"Jul (31)","key":"10.1016\/j.vaccine.2012.12.031_bib0160","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1016\/j.vaccine.2010.05.006","article-title":"Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine","volume":"28","author":"Zollinger","year":"2010","journal-title":"Vaccine"},{"issue":"June (24)","key":"10.1016\/j.vaccine.2012.12.031_bib0165","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1016\/j.vaccine.2006.03.091","article-title":"Neisseria meningitidis group B correlates of protection and assay standardization\u2013international meeting report Emory University, Atlanta, Georgia, United States, 16\u201317 March 2005","volume":"24","author":"Borrow","year":"2006","journal-title":"Vaccine"},{"issue":"January (7\u20138)","key":"10.1016\/j.vaccine.2012.12.031_bib0170","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","article-title":"Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease","volume":"21","author":"Holst","year":"2003","journal-title":"Vaccine"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2012.12.031_bib0175","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"issue":"February (15)","key":"10.1016\/j.vaccine.2012.12.031_bib0180","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/S0264-410X(99)00423-5","article-title":"Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2\u20133 and 7\u20138 years of age","volume":"18","author":"de Kleijn","year":"2000","journal-title":"Vaccine"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2012.12.031_bib0185","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1086\/514232","article-title":"Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland","volume":"177","author":"Perkins","year":"1998","journal-title":"J Infect Dis"},{"issue":"April (16)","key":"10.1016\/j.vaccine.2012.12.031_bib0190","first-page":"1520","article-title":"Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile","volume":"281","author":"Tappero","year":"1999","journal-title":"JAMA"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2012.12.031_bib0195","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1128\/IAI.71.4.1650-1655.2003","article-title":"Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine","volume":"71","author":"Vermont","year":"2003","journal-title":"Infect Immun"},{"issue":"February (7)","key":"10.1016\/j.vaccine.2012.12.031_bib0200","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.vaccine.2010.12.039","article-title":"A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression","volume":"29","author":"Keiser","year":"2011","journal-title":"Vaccine"},{"issue":"October (44)","key":"10.1016\/j.vaccine.2012.12.031_bib0205","doi-asserted-by":"crossref","first-page":"7752","DOI":"10.1016\/j.vaccine.2011.07.124","article-title":"An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups","volume":"29","author":"Pinto","year":"2011","journal-title":"Vaccine"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2012.12.031_bib0210","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1128\/CVI.00070-12","article-title":"Analysis of the bactericidal response to an experimental Neisseria meningitidis vesicle vaccine","volume":"19","author":"Moran","year":"2012","journal-title":"Clin Vaccine Immunol"},{"issue":"September (9)","key":"10.1016\/j.vaccine.2012.12.031_bib0215","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1128\/CVI.00129-10","article-title":"Three doses of an experimental detoxified L3-derived lipooligosaccharide meningococcal vaccine offer good safety but low immunogenicity in healthy young adults","volume":"17","author":"Bonvehi","year":"2010","journal-title":"Clin Vaccine Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12018154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12018154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,19]],"date-time":"2020-07-19T13:00:21Z","timestamp":1595163621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12018154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0264410X12018154"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.12.031","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}